Welcome to VIRTTU
VIRTTU Biologics is a clinical stage biotechnology company pioneering the development of viruses to treat cancer.
By remodeling a common virus we have developed and patented a series of novel therapies that have the potential to transform treatment and target many forms of cancer effectively.
Our most advanced programme, a unique cancer-destroying (oncolytic) virus, has the potential to radically change oncology therapy through its ability to seek out and multiply only in cancer cells: destroying them while leaving healthy cells unaffected.
We are now actively advancing the clinical development programme required to secure regulatory approval to market our lead programme, SEPREHVIR®, for use in cancer therapy.
Virttu Biologics confirms treatment of third cohort of patients in Phase I/IIa SEPREHVIR Study in Mesothelioma and expands recruitment to the Study
Virttu Biologics confirms treatment of third cohort of patients in Phase I/IIa SEPREHVIR Study in Mesothelioma and expands recruitment to the Study. Virttu Biologics has announced the completion of the third cohort of patients in the Phase I/IIa Dose Escalating Study of SEPREHVIR (HSV1716) in patients with malignant pleural mesothelioma (a type of lung cancer) and that it will activate an expansion of the Study.
Hopeful monsters - Tumour Heterogeneity vs Oncolytic Viruses
The recent NCRI Cancer Conference provided a fascinating insight into the latest developments in understanding cancer development and treatment including the new understanding of clonal diversity of tumours and associated cancer genome evolution